Katharine Hutchison1, Anna Page1, Samuel Hayward2. 1. Gastrointestinal and Liver Services, Somerset NHS Foundation Trust, Taunton, UK. 2. Public Health, North Somerset Council, Clevedon, UK.
WHO is aiming for the eradication of the hepatitis C virus (HCV) as a global health threat by 2030. However, concerns have been raised about how the COVID-19 pandemic may affect eradication efforts.1One long-standing barrier to achieving the WHO goals is the high prevalence of HCV in marginalised populations.2 Homelessness is a significant risk factor for HCV infection in the UK, with chronic prevalence in this group estimated at 29%.3 Homeless people diagnosed with HCV infection are also less likely to complete treatment. The reasons for this are complex, but involve mistrust of medical services, inflexibility of secondary care pathways and geographic mobility.4During the COVID-19 pandemic, homeless people across Somerset were housed in temporary accommodation through the national ‘Everyone in’ initiative. This provided a unique opportunity for eradication efforts by reducing the geographic mobility of this population, and provided a setting in which HCV patients could be managed. In this letter, we describe a targeted multidisciplinary programme to identify and treat HCV infection within the Somerset homeless population.Across Somerset, 137 homeless people were accommodated in 8 settings. Healthcare link workers opportunistically offered dried blood spot tests (DBSTs) to all residents, screening for HCV. Patients testing positive for HCV RNA were reviewed in a one-stop clinic by hepatology specialist nurse. Blood tests for viral load and genotyping were taken and a fibroscan performed. Cases were then commenced on direct acting antivirals. DBST was repeated on completion of treatment and at 3 months to ensure attainment of sustained virological response. To remove barriers, healthcare link workers could accompany patients to appointments and could dispense medications daily at accommodation sites if required.Across 8 settings, 103 people were screened (75.2% of total population). Results were obtained for 92 (89.4%), with 11 awaiting results or repeat tests. Fifty-nine (63.4%) screened negative for HCV antibodies. Thirty-one (33.7%) screened positive for HCV antibodies; of these, 14 (15.2%) were HCV RNA positive, indicating chronic infection. Eleven patients (78.6%) have been assessed in clinic, and 8 patients (57.1%) have begun antiviral treatment. The remainder are awaiting assessment or for treatment to commence (see table 1).
Table 1
Screening results
Demographics
No
Percentage
Total screened
103
/
Gender
Male
68
66.0
Female
35
34.0
Age
39 (24–61)
/
Risk factors
Risk factor/s identified
35
70.0
Intravenous drug user
30
60.0
Sexual
6
12.0
Alcohol
*
*
Mental health
*
*
Results
No
Percentage
Negative result
59
63.4
Awaiting result
5
4.9
HCV PCR+
14
15.2
HCV Ab+
31
33.7
HCV PCR+andAb+
14
15.2
Retest required
12
11.7
Retest for test failure
6
5.8
Retest for equivocal result
6
5.8
Treatment
No
Percentage
Clinical assessment completed
11
78.6
Treatment initiated
8
57.1
Treatment completed
*
*
Uptake
95% CI
Setting
Eligible
Screened
Uptake
Lower CI
Upper CI
Setting 1
34
34
100.0%
100.0%
100.0%
Setting 2
45
27
60.0%
41.5%
78.5%
Setting 3
25
20
80.0%
62.5%
97.5%
Setting 4
12
8
66.7%
34.0%
99.3%
Setting 5
*
*
*
*
*
Setting 6
*
*
*
*
*
Setting 7
*
*
*
*
*
Other settings
*
*
*
*
*
Total
137
103
75.2%
66.8%
83.5%
Coverage
95% CI
Setting
Eligible
Result
Coverage
Lower CI
Upper CI
Setting 1
34
33
100.0%
100.0%
100.0%
Setting 2
45
24
53.3%
33.4%
73.3%
Setting 3
25
19
76.0%
56.8%
95.2%
Setting 4
12
*
*
*
*
Setting 5
*
*
*
*
*
Setting 6
*
*
*
*
*
* denoting value <5.
HCV, hepatitis C virus.
Screening results* denoting value <5.HCV, hepatitis C virus.At time of writing, all patients diagnosed with HCV infection have been engaged for assessment and treatment. This, and high uptake, represent ongoing engagement with the programme and demonstrates the effectiveness of the model.Our results demonstrate that community-based programmes are an effective way to identify and treat HCV infection in homeless populations. This approach was enabled by the provision of emergency accommodation due to the COVID-19 pandemic, which provided population stability, reducing barriers to treatment. Additionally, healthcare link workers simplified the screening and treatment process and provided flexibility for patients, giving them control over their health and encouraging them to engage with services.Going forward, opportunities to provide stable accommodation and to engage patients when they are less geographically mobile should be actively sought. As ‘lockdowns’ continue internationally, there may be scope for local healthcare teams to replicate this work in their community as the global effort to eliminate HCV continues.
About
Arc works across Taunton, West Somerset and Sedgemoor, to house, support and enable homeless people to maximise their potential. They strive for all homeless people to have a safe and supportive environment, where people can be inspired and empowered by their own strengths. ARC inspires healthcare link workers delivered the screening programme within accommodation settings run or supported by the organisation (www.arcinspire.co.uk).Somerset National Health Service Foundation Trust provides community, mental health and acute hospital services in Somerset, England. Hepatitis nurse specialists, based at Musgrove Park Hospital, provided oversite of the screening programme, clinical assessment and treatment for cases (www.somersetft.nhs.uk).Somerset County Council’s Public Health team work across the county to reduce health inequalities and increase life expectancy. They work through a wide range of targeted public health programmes to promote better health. The team provided support for the screening programme and liaised with wider stakeholders to develop care pathways (www.somerset.gov.uk/social-care-and-health/public-health).
Authors: G V Papatheodoridis; A Hatzakis; E Cholongitas; R Baptista-Leite; I Baskozos; J Chhatwal; M Colombo; H Cortez-Pinto; A Craxi; D Goldberg; C Gore; A Kautz; J V Lazarus; L Mendão; M Peck-Radosavljevic; H Razavi; E Schatz; N Tözün; P van Damme; H Wedemeyer; Y Yazdanpanah; F Zuure; M P Manns Journal: J Viral Hepat Date: 2018-03 Impact factor: 3.728
Authors: John S Lambert; Ross Murtagh; Dee Menezes; Austin O'Carroll; Carol Murphy; Walter Cullen; Tina McHugh; Gordana Avramovic; Willard Tinago; Marie Claire Van Hout Journal: BMC Infect Dis Date: 2019-02-07 Impact factor: 3.090